Stevanato Group (NYSE:STVN) Announces Earnings Results, Misses Expectations By $0.01 EPS

Stevanato Group (NYSE:STVN) announced its quarterly earnings results on Tuesday. The company reported €0.12 ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of €0.13 ($0.14) by (€0.01) (($0.01)), Briefing.com reports. Stevanato Group had a net margin of 11.27% and a return on equity of 10.89%. The company had revenue of €277.90 million during the quarter, compared to analysts’ expectations of €274.36 million. During the same period last year, the firm earned $0.16 earnings per share. Stevanato Group’s revenue was up 2.4% on a year-over-year basis. Stevanato Group updated its FY 2024 guidance to 0.517-0.539 EPS and its FY24 guidance to €0.47-0.49 EPS.

Stevanato Group Stock Performance

Shares of Stevanato Group stock traded down €0.01 ($0.01) on Thursday, reaching €22.54 ($24.77). 164,673 shares of the stock were exchanged, compared to its average volume of 509,713. Stevanato Group has a 1-year low of €16.56 ($18.20) and a 1-year high of €34.73 ($38.16). The company has a current ratio of 1.74, a quick ratio of 1.13 and a debt-to-equity ratio of 0.19. The business has a fifty day moving average price of €19.66 and a two-hundred day moving average price of €20.31.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on STVN shares. Morgan Stanley reduced their target price on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Citigroup reduced their target price on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, August 7th.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.